VivoSim Labs Inc Financials
This page shows VivoSim Labs Inc (VIVS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 17 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
VivoSim Labs Inc has an operating margin of -8761.1%, meaning the company retains $-8761 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -13840.4% the prior year.
VivoSim Labs Inc's revenue surged 32.1% year-over-year to $144K, reflecting rapid business expansion. This strong growth earns a score of 100/100.
VivoSim Labs Inc carries a low D/E ratio of 0.40, meaning only $0.40 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 3.25, VivoSim Labs Inc holds $3.25 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
While VivoSim Labs Inc generated -$9.5M in operating cash flow, capex of $13K consumed most of it, leaving -$9.5M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.
VivoSim Labs Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, neither operating efficiency signal passes.
For every $1 of reported earnings, VivoSim Labs Inc generates $3.80 in operating cash flow (-$9.5M OCF vs -$2.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
VivoSim Labs Inc earns $-1261.6 in operating income for every $1 of interest expense (-$12.6M vs $10K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
VivoSim Labs Inc generated $144K in revenue in fiscal year 2025. This represents an increase of 32.1% from the prior year.
VivoSim Labs Inc's EBITDA was -$12.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 16.6% from the prior year.
VivoSim Labs Inc generated -$9.5M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 35.5% from the prior year.
VivoSim Labs Inc reported -$2.5M in net income in fiscal year 2025. This represents an increase of 83.0% from the prior year.
VivoSim Labs Inc earned $-1.70 per diluted share (EPS) in fiscal year 2025. This represents an increase of 91.2% from the prior year.
VivoSim Labs Inc held $11.3M in cash against $0 in long-term debt as of fiscal year 2025.
VivoSim Labs Inc had 2M shares outstanding in fiscal year 2025. This represents an increase of 126.0% from the prior year.
VivoSim Labs Inc's gross margin was 96.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
VivoSim Labs Inc's operating margin was -8761.1% in fiscal year 2025, reflecting core business profitability. This is up 5079.3 percentage points from the prior year.
VivoSim Labs Inc's net profit margin was -1727.8% in fiscal year 2025, showing the share of revenue converted to profit. This is up 11731.9 percentage points from the prior year.
VivoSim Labs Inc invested $5.0M in research and development in fiscal year 2025. This represents a decrease of 8.6% from the prior year.
VivoSim Labs Inc invested $13K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 69.0% from the prior year.
VIVS Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $26-99.9% | $28K-24.3% | $37K+54.2% | $24K-20.0% | $30K-23.1% | $39K+680.0% | $5K | $0 |
| Cost of Revenue | $2 | $0 | $0-100.0% | $2K+100.0% | $1K-50.0% | $2K | $0 | $0 |
| Gross Profit | $24-99.9% | $28K-24.3% | $37K+68.2% | $22K-24.1% | $29K-21.6% | $37K+640.0% | $5K | $0 |
| R&D Expenses | $1K-99.9% | $923K-7.8% | $1.0M-43.8% | $1.8M+80.9% | $984K-29.8% | $1.4M-2.2% | $1.4M+7.4% | $1.3M |
| SG&A Expenses | $2K-99.9% | $1.7M-10.8% | $2.0M+14.1% | $1.7M+3.4% | $1.7M-18.2% | $2.0M-10.2% | $2.3M-19.0% | $2.8M |
| Operating Income | $3K+100.1% | -$2.6M+9.6% | -$2.9M+15.9% | -$3.5M-33.0% | -$2.6M+23.0% | -$3.4M+8.0% | -$3.7M+10.6% | -$4.1M |
| Interest Expense | $4 | $0-100.0% | $4K-20.0% | $5K | $0 | $0 | $0 | N/A |
| Income Tax | $2-99.9% | $2K | $0 | $0 | $0-100.0% | $2K | $0 | $0 |
| Net Income | $3K+100.1% | -$2.5M+10.5% | -$2.8M+17.5% | -$3.4M-35.2% | -$2.5M+23.8% | -$3.3M+7.2% | -$3.6M+9.8% | -$4.0M |
| EPS (Diluted) | $1.03+205.1% | $-0.98+14.0% | $-1.14 | $-2.28-35.7% | $-1.68+38.7% | $-2.74-585.0% | $-0.40+13.0% | $-0.46 |
VIVS Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $7K-99.9% | $9.7M-19.1% | $12.0M+211.6% | $3.8M-43.1% | $6.8M-28.7% | $9.5M+6.6% | $8.9M-20.4% | $11.2M |
| Current Assets | $6K-99.9% | $7.6M-21.6% | $9.7M+360.9% | $2.1M-56.1% | $4.8M-34.3% | $7.3M+16.7% | $6.2M-24.8% | $8.3M |
| Cash & Equivalents | $4K-99.9% | $6.7M-26.3% | $9.1M+679.9% | $1.2M-63.4% | $3.2M-48.7% | $6.2M+16.8% | $5.3M-30.5% | $7.6M |
| Inventory | $0 | N/A | N/A | $0-100.0% | $640K+56.9% | $408K | N/A | N/A |
| Accounts Receivable | $33-99.9% | $32K0.0% | $32K+23.1% | $26K-10.3% | $29K-39.6% | $48K+45.5% | $33K-40.0% | $55K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3K-99.9% | $2.6M+7.4% | $2.4M-29.9% | $3.5M+13.2% | $3.1M+9.5% | $2.8M+4.0% | $2.7M-0.2% | $2.7M |
| Current Liabilities | $2K-99.9% | $2.4M+14.3% | $2.1M-27.1% | $2.9M+21.7% | $2.4M+18.7% | $2.0M+19.6% | $1.7M+6.3% | $1.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $4K-99.9% | $7.1M-25.9% | $9.5M+2520.3% | $364K-90.1% | $3.7M-44.8% | $6.7M+7.8% | $6.2M-26.9% | $8.5M |
| Retained Earnings | $350K+100.1% | -$347.5M-0.7% | -$345.0M+1.1% | -$349.0M-1.0% | -$345.6M-0.7% | -$343.0M-1.9% | -$336.6M-1.1% | -$333.0M |
VIVS Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $9K+100.4% | -$2.4M+39.6% | -$3.9M-118.8% | -$1.8M+31.8% | -$2.6M+11.4% | -$3.0M+15.3% | -$3.5M-11.8% | -$3.1M |
| Capital Expenditures | $13 | N/A | N/A | $0-100.0% | $13K | $0 | $0-100.0% | $27K |
| Free Cash Flow | $9K | N/A | N/A | -$1.8M+32.2% | -$2.7M+11.0% | -$3.0M+15.3% | -$3.5M-10.9% | -$3.2M |
| Investing Cash Flow | $24 | $0 | $0-100.0% | $4K | $0-100.0% | $20K-25.9% | $27K+125.0% | $12K |
| Financing Cash Flow | $2K | $0-100.0% | $1.7M+879.2% | -$216K+41.8% | -$371K-105.9% | $6.2M+432.7% | $1.2M | $0 |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
VIVS Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q3'23 | Q2'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 92.3%-7.7pp | 100.0%0.0pp | 100.0%+8.3pp | 91.7%-5.0pp | 96.7%+1.8pp | 94.9%-5.1pp | 100.0% | N/A |
| Operating Margin | 10576.9%+19987.6pp | -9410.7%-1532.3pp | -7878.4%+6571.6pp | -14450.0%-5756.7pp | -8693.3%-11.3pp | -8682.0%+64917.9pp | -73600.0% | N/A |
| Net Margin | 10350.0%+19439.3pp | -9089.3%-1405.5pp | -7683.8%+6678.7pp | -14362.5%-5865.8pp | -8496.7%+77.7pp | -8574.4%+63505.6pp | -72080.0% | N/A |
| Return on Equity | 60.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | 38.7%+64.9pp | -26.3%-2.5pp | -23.7%+65.9pp | -89.7%-51.9pp | -37.7%-2.4pp | -35.3%+5.3pp | -40.6%-4.8pp | -35.8% |
| Current Ratio | 2.44-0.7 | 3.10-1.4 | 4.52+3.8 | 0.71-1.3 | 1.98-1.6 | 3.58-0.1 | 3.67-1.5 | 5.18 |
| Debt-to-Equity | 0.57+0.2 | 0.37+0.1 | 0.26-9.3 | 9.56+8.7 | 0.84+0.4 | 0.42-0.0 | 0.44+0.1 | 0.32 |
| FCF Margin | 32984.6% | N/A | N/A | -7504.2%+1345.8pp | -8850.0%-1201.3pp | -7648.7%+62791.3pp | -70440.0% | N/A |
Similar Companies
Frequently Asked Questions
What is VivoSim Labs Inc's annual revenue?
VivoSim Labs Inc (VIVS) reported $144K in total revenue for fiscal year 2025. This represents a 32.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is VivoSim Labs Inc's revenue growing?
VivoSim Labs Inc (VIVS) revenue grew by 32.1% year-over-year, from $109K to $144K in fiscal year 2025.
Is VivoSim Labs Inc profitable?
No, VivoSim Labs Inc (VIVS) reported a net income of -$2.5M in fiscal year 2025, with a net profit margin of -1727.8%.
What is VivoSim Labs Inc's earnings per share (EPS)?
VivoSim Labs Inc (VIVS) reported diluted earnings per share of $-1.70 for fiscal year 2025. This represents a 91.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is VivoSim Labs Inc's EBITDA?
VivoSim Labs Inc (VIVS) had EBITDA of -$12.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is VivoSim Labs Inc's gross margin?
VivoSim Labs Inc (VIVS) had a gross margin of 96.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is VivoSim Labs Inc's operating margin?
VivoSim Labs Inc (VIVS) had an operating margin of -8761.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is VivoSim Labs Inc's net profit margin?
VivoSim Labs Inc (VIVS) had a net profit margin of -1727.8% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is VivoSim Labs Inc's free cash flow?
VivoSim Labs Inc (VIVS) generated -$9.5M in free cash flow during fiscal year 2025. This represents a 35.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is VivoSim Labs Inc's operating cash flow?
VivoSim Labs Inc (VIVS) generated -$9.5M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are VivoSim Labs Inc's total assets?
VivoSim Labs Inc (VIVS) had $14.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are VivoSim Labs Inc's capital expenditures?
VivoSim Labs Inc (VIVS) invested $13K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does VivoSim Labs Inc spend on research and development?
VivoSim Labs Inc (VIVS) invested $5.0M in research and development during fiscal year 2025.
How many shares does VivoSim Labs Inc have outstanding?
VivoSim Labs Inc (VIVS) had 2M shares outstanding as of fiscal year 2025.
What is VivoSim Labs Inc's current ratio?
VivoSim Labs Inc (VIVS) had a current ratio of 3.25 as of fiscal year 2025, which is generally considered healthy.
What is VivoSim Labs Inc's debt-to-equity ratio?
VivoSim Labs Inc (VIVS) had a debt-to-equity ratio of 0.40 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is VivoSim Labs Inc's return on assets (ROA)?
VivoSim Labs Inc (VIVS) had a return on assets of -17.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is VivoSim Labs Inc's cash runway?
Based on fiscal year 2025 data, VivoSim Labs Inc (VIVS) had $11.3M in cash against an annual operating cash burn of $9.5M. This gives an estimated cash runway of approximately 14 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is VivoSim Labs Inc's Piotroski F-Score?
VivoSim Labs Inc (VIVS) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are VivoSim Labs Inc's earnings high quality?
VivoSim Labs Inc (VIVS) has an earnings quality ratio of 3.80x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can VivoSim Labs Inc cover its interest payments?
VivoSim Labs Inc (VIVS) has an interest coverage ratio of -1261.6x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is VivoSim Labs Inc?
VivoSim Labs Inc (VIVS) scores 59 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.